Is Gleevec (STI571) used for any type of cancer other than CML?
Gleevec (STI571) was originally developed to inhibit a particular enzyme (tyrosine Kinase) which is produced by the Bcr-Abl oncogene and is believed to drive the unregulated production of white blood cells. The Bcr-Abl oncogene is present in 95% of CML (Chronic Myelogenous Leukemia) patients and about 20% of ALL (Acute Lymphoblastic Leukemia) patients. Other forms of leukemia which do not have the Bcr-Abl mutation would not likely benefit from Gleevec although there has been some discussion about trying it in some other leukemias. Further laboratory experiments have shown that Gleevec (STI571) also inhibits a protein called C-Kit and PDGF (Platelet Derived Growth Factor). C-Kit and PDGF may play a role in certain other cancers. Trials are now underway on GIST (Gastro Intestinal Stromal Tumor) and have shown very promising early results. Trials are now starting or are about to begin on several other forms of cancer. The Novartis statement below, references these other cancer trials. Cli
